Jubilant Biosys, a subsidiary of Jubilant Pharmova, has signed a Shareholders' Agreement with Pierre Fabre, subscribing to 80% of JASMIN's equity capital and successfully acquiring PF's R&D Centre in France; the transaction was closed on March 19, 2025.